Detection of diagnostic and prognostic methylation-based signatures in liquid biopsy specimens from patients with meningiomas

Recurrence of meningiomas is unpredictable by current invasive methods based on surgically removed specimens. Identification of patients likely to recur using noninvasive approaches could inform treatment strategy, whether intervention or monitoring. In this study, we analyze the DNA methylation lev...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 14; no. 1; pp. 5669 - 19
Main Authors Herrgott, Grayson A, Snyder, James M, She, Ruicong, Malta, Tathiane M, Sabedot, Thais S, Lee, Ian Y, Pawloski, Jacob, Podolsky-Gondim, Guilherme G, Asmaro, Karam P, Zhang, Jiaqi, Cannella, Cara E, Nelson, Kevin, Thomas, Bartow, deCarvalho, Ana C, Hasselbach, Laura A, Tundo, Kelly M, Newaz, Rehnuma, Transou, Andrea, Morosini, Natalia, Francisco, Victor, Poisson, Laila M, Chitale, Dhananjay, Mukherjee, Abir, Mosella, Maritza S, Robin, Adam M, Walbert, Tobias, Rosenblum, Mark, Mikkelsen, Tom, Kalkanis, Steven, Tirapelli, Daniela P C, Weisenberger, Daniel J, Carlotti, Jr, Carlos G, Rock, Jack, Castro, Ana Valeria, Noushmehr, Houtan
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 13.09.2023
Nature Publishing Group UK
Nature Portfolio
Subjects
Artificial Intelligence
Biopsy
Blood
Brain cancer
Central nervous system
DNA Methylation
Humans
Liquid Biopsy
Meningeal Neoplasms - diagnosis
Meningeal Neoplasms - genetics
Meningioma
Meningioma - diagnosis
Meningioma - genetics
Patients
Prognosis
Strategy
Tumors
Online AccessGet full text

Cover

More Information
Summary:Recurrence of meningiomas is unpredictable by current invasive methods based on surgically removed specimens. Identification of patients likely to recur using noninvasive approaches could inform treatment strategy, whether intervention or monitoring. In this study, we analyze the DNA methylation levels in blood (serum and plasma) and tissue samples from 155 meningioma patients, compared to other central nervous system tumor and non-tumor entities. We discover DNA methylation markers unique to meningiomas and use artificial intelligence to create accurate and universal models for identifying and predicting meningioma recurrence, using either blood or tissue samples. Here we show that liquid biopsy is a potential noninvasive and reliable tool for diagnosing and predicting outcomes in meningioma patients. This approach can improve personalized management strategies for these patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-023-41434-z